Immusoft Receives $8M in Funding from the California Institute for Regenerative Medicine - FinSMEs

Immusoft of CA, a San Francisco, CA-based wholly owned subsidiary of Immusoft Corporation, a clinical-stage compartment therapy institution dedicated to improving the lives of patients with uncommon oregon familial diseases, raised $8M successful backing from California Institute for Regenerative Medicine (CIRM).

The institution intends to usage the funds to beforehand its engineered B compartment objective program. This backing volition enactment a Phase I survey to measure the information and tolerability of ISP-001 (for transportation of alpha-L-iduronidase, oregon IDUA) successful MPS I a rare, puerility familial disease.

Led by Sean Ainsworth, Chief Executive Officer, and Robert Hayes, Chief Scientific Officer, Immusoft is advancing ISP-001, which is simply a caller level that uses a compartment therapy to present a gene-encoded medicine. The level leverages the B cell’s earthy quality to nutrient precocious levels of antibody proteins. It is an engineered B compartment therapy to participate into quality objective trials. With ISP-001, patient’s B cells are programmed to perpetually nutrient therapeutic proteins, perchance mitigating the request for predominant infusions portion perchance improving diligent outcomes.

The institution has received FDA Orphan Drug Designation and Rare Pediatric Disease Designation for ISP-001 successful MPS I (Mucopolysaccharidosis benignant I).

In summation to the enactment for its MPS I objective trial, successful November 2021, Immusoft received a $4M CIRM grant to enactment the improvement of its ISP-002 (for transportation of iduronate sulfatase) programme for MPS II. Immusoft has besides entered into a probe collaboration and licence enactment statement with Takeda Pharmaceutical Company Limited aimed astatine delivering macromolecule therapeutics crossed the blood-brain obstruction to dainty neurometabolic disorders.

FinSMEs

28/01/2023